NCT03856853

Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease

A Phase III, Randomized, Double-blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Pirfenidone in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 144 (estimated)
• Sponsor: Beijing Continent Pharmaceutical Co, Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the eEfficacy and safety of pirfenidone in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)

Conditions

• Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)

Interventions

Type	Name	Description
DRUG	Pirfenidone	pirfenidone for SSc-ILD treatment
OTHER	placebo	as control

Timeline

• Start date: 2018-06-15
• Primary completion: 2021-02-10
• Completion: 2021-05-10
• First posted: 2019-02-27
• Last updated: 2019-02-27

Locations

1 site across 1 country: China